Skip to content

effect of budesonide on the incidence of PRAEs in children with URI undergoing cardiac therapeutic catheterization

effect of budesonide on the incidence of PRAEs in children with URI undergoing cardiac therapeutic catheterization

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034531
Enrollment
Unknown
Registered
2020-07-08
Start date
2020-07-13
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHD AND URI

Interventions

experimental group:budesonide inhaled
control group:saline inhaled

Sponsors

Shanghai Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0.5 Years to 16 Years

Inclusion criteria

Inclusion criteria: Children with recent URI, aged up to 16 years, ASA Physical Status 2 or 3, and undergoing elective interventional cardiac catheterisation (transcatheter atrial septal defect closure, transcatheter ventricular septal defect closure or transcatheter patent ductus arteriosus closure) were assessed for eligibility in this study.

Exclusion criteria

Exclusion criteria: The exclusion criteria included evidence of lower respiratory tract infection within the previous 2 weeks, complex cyanotic heart disease, known hypersensitivity to specific anaesthetic agents, chronic liver or renal diseases, recent participation in other clinical studies, use of endotracheal tube or regional anaesthesia.

Design outcomes

Primary

MeasureTime frame
incidence of PRAEs;Incidence of cough within 24 hours after operation;

Secondary

MeasureTime frame
Incidence of PRAEs within 24 hours after operation;

Countries

China

Contacts

Public ContactZhang Kan

Shanghai Children's Medical Center

649508943@qq.com+86 15002178102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026